Company / Working Capital
Moleculin Biotech, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$2.8M
FY2025
5-year range
-$165.0K / $68.9M
FY2021-FY2025
Trend
+1816.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital changed +1816% YoY in FY2025, a notable deviation from the 9-year average annual change of +246%.
Based on SEC 10-K filings.
$3M in FY2025 with a 5-year CAGR of -27.6%.
Declined from $19M to $3M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -58.9%
- 5-Year CAGR
- -27.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -27.6%, indicating a declining trend.
- In FY2025, working capital increased 1816.4% year-over-year.
- Peak working capital was recorded in FY2021.
- Lowest working capital in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -3.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.8M | +1816.4% |
| FY2024 | -$165.0K | -100.8% |
| FY2023 | $19.5M | -52.3% |
| FY2022 | $40.8M | -40.8% |
| FY2021 | $68.9M | +382.4% |
| FY2020 | $14.3M | +44.0% |
| FY2019 | $9.9M | +142.0% |
| FY2018 | $4.1M | -32.7% |
| FY2017 | $6.1M | +57.0% |
| FY2016 | $3.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026